For the quarter ending 2025-09-30, CPIX made $8,292,362 in revenue. -$1,940,764 in net income. Net profit margin of -23.40%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Net revenues | 8,292,362 | 10,837,363 | 9,466,635 | 9,085,826 |
| Cost of products sold | 988,760 | 2,011,389 | 1,776,007.5 | 1,323,013 |
| Selling and marketing | 4,433,831 | 4,223,647 | 4,188,571 | 4,397,480 |
| Research and development | 1,253,367 | 1,468,399 | 1,225,462 | 1,306,095 |
| General and administrative | 2,572,066 | 2,874,922 | 2,847,186.5 | 2,675,380 |
| Amortization | 1,009,598 | 1,006,484 | 1,285,052.5 | 1,078,290 |
| Total costs and expenses | 10,257,622 | 11,584,841 | 11,322,279.5 | 10,780,258 |
| Operating loss | -1,965,260 | -747,478 | -1,855,644.5 | -1,694,432 |
| Interest income | 131,583 | 127,489 | 101,706.5 | 69,190 |
| Other income - insurance proceeds | 0 | - | 0 | 237,089 |
| Interest expense | 109,699 | 109,547 | 170,893.5 | 137,374 |
| Loss before income taxes | -1,943,376 | -729,536 | -1,924,831.5 | -1,525,527 |
| Income tax expense | 5,670 | 5,671 | -22,777 | 11,442 |
| Net loss | -1,949,046 | -735,207 | -1,902,054.5 | -1,536,969 |
| Net loss (income) at subsidiary attributable to noncontrolling interests | -8,282 | 5,533 | 22,984 | 7,112 |
| Net loss attributable to common shareholders | -1,940,764 | -740,740 | -1,925,038.5 | -1,544,081 |
| Basic (in shares) | 14,958,534 | 14,960,596 | -7,055,286.5 | 14,052,754 |
| Basic (in usd per share) | -0.13 | -0.05 | -0.135 | -0.11 |
| Diluted (in shares) | 14,958,534 | 14,960,596 | -7,055,286.5 | 14,052,754 |
| Diluted (in usd per share) | -0.13 | -0.05 | -0.135 | -0.11 |
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)